Announced Mon, 10 Aug · 16:28 IST
Gland Pharma Q1FY27: Revenue up 20%, PAT up 47% YoY
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+7.9%1-day move
₹2670.00
prior close
₹2845.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.6+2.1+2.6+4.2+7.9+11.0+11.1+8.7+6.9+6.7————
Up moveDown movePending
AI summary
Gland Pharma posted record Q1FY27 results. Revenue rose 20% YoY to Rs 18,003 Mn, driven by USA (32% growth) and Europe (20%). PAT jumped 47% to Rs 3,170 Mn with margins expanding 330 bps to 18%. Adj. EBITDA margin grew to 28%. CDMO and B2B each contributed 50% of revenue. R&D spend was Rs 772 Mn. QoQ PAT declined 14%.
Likely market impact
Strong quarter with double-digit revenue and profit growth, margin expansion, and new CDMO partnerships. Positive for stock sentiment.